BRCA1 and hyperinsulinemic hypoglycemia, familial, 4: Further supporting personalized treatment strategies, research indicates that tumors with BRCA1/2 mutations or those characterized by homologous recombination deficiency may benefit more from treatment with PARP inhibitors (63).